Two oral GLP-1 medications for weight management have now been approved in the United States, removing the injection from the decision for the first time. That lowers one barrier to starting treatment without changing anything about what a safe prescribing evaluation requires.
The FDA approved a once-daily oral semaglutide tablet for chronic weight management in December 2025, the first oral GLP-1 cleared for that use, with a launch in early January. On April 1 of this year, it approved orforglipron, a nonpeptide oral GLP-1 receptor agonist marketed as Foundayo, for adults with obesity or overweight with at least one weight-related condition. Orforglipron is notable because it can be taken at any time of day without the fasting and water restrictions the earlier oral formulation requires.
At the same time, federal regulators have spent nearly a year sending warning letters to telehealth companies over how these medications are marketed. The gap between a persuasive advertisement and an adequate clinical workup is where avoidable harm happens.
The Marketing Environment Around These Drugs
Understanding the promotional context is part of understanding the medical decision, because the two now arrive together.
Beginning in September 2025, the FDA opened a broad enforcement push against direct-to-consumer prescription drug advertising. Since then, it has issued three major rounds of letters largely aimed at telehealth companies marketing compounded GLP-1 products, including a batch of thirty letters announced in March and another wave of twenty-five letters in mid-June. The agency has alleged that companies made false or misleading claims, including implying that compounded products are the same as FDA-approved ones and obscuring who actually compounded them.
The distinction the agency is drawing is real. Compounded semaglutide and tirzepatide are not FDA-approved products. The agency does not review their safety, effectiveness or quality before they are marketed, which is a different regulatory status from the branded medications, not a different price point for the same thing. Compounded drugs are also not the same as generics, which are FDA-approved.
Celebrity ambassadors and paid partnerships are also now a routine part of how these treatments reach consumers. An endorsement is a commercial arrangement. It carries no information about whether a medication is appropriate for the person watching it.
The Workup a Prescriber Should Actually Do
A short online questionnaire that captures height, weight, and a credit card does not meet the standard of care, whether the platform is virtual or in person.
A proper evaluation starts with confirming the medication is indicated. These drugs are approved for adults with a body mass index of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia or obstructive sleep apnea.
Baseline laboratory work generally includes hemoglobin A1c or fasting glucose, a comprehensive metabolic panel covering kidney and liver function, a lipid panel and, where clinically relevant, thyroid function. Baseline values matter for monitoring later, not only for eligibility.
Medical and family history carries specific weight in this class. Approved GLP-1 receptor agonists for weight management carry a boxed warning for thyroid C-cell tumors based on rodent data, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A history of pancreatitis, gallbladder disease, gastroparesis, diabetic retinopathy or significant kidney impairment all change the calculation. Prescribing labels also advise against combining these agents with other GLP-1 products.
Medication review matters because delayed gastric emptying affects absorption of other drugs, and combining these agents with insulin or sulfonylureas raises hypoglycemia risk without dose adjustment. Pregnancy status and contraception should be addressed, as should a plan for what happens if a person becomes pregnant.
Screening for disordered eating belongs in the evaluation. Appetite-suppressing medication interacts poorly with an active eating disorder, and a prescriber should ask rather than assume.
Any clinician prescribing these medications should be able to discuss the common gastrointestinal effects, which are the most frequently reported adverse reactions, alongside the rarer risks listed in the prescribing information, including pancreatitis, gallbladder disease, kidney injury related to dehydration, and psychiatric adverse effects.
The Two Conversations Most Often Skipped
Weight loss on these medications includes lean mass, not only fat mass. That is a well-documented feature of rapid weight reduction generally, and it makes adequate protein intake and resistance training part of the treatment plan rather than optional extras. A prescriber who never raises nutrition or strength work is treating a number rather than a person.
The second conversation is what happens when the medication stops. Obesity is managed as a chronic condition, and appetite regulation generally returns toward baseline after discontinuation. Weight regain following cessation is expected rather than a personal failure. Cost changes, insurance denials, supply interruptions, and side effects all cause people to stop, and knowing that in advance changes how someone plans.
Coverage itself deserves a direct question before starting. Many employer plans exclude weight management medications, prior authorization is common, and manufacturer and pharmacy cash-pay programs have shifted repeatedly.
Practical Steps Before Starting Anything
Ask any prescriber, including a telehealth one, whether a licensed clinician will review a full medical and family history and whether baseline labs are required. If neither happens, that is a reason to look elsewhere.
Confirm which product is being dispensed. Ask whether it is an FDA-approved medication or a compounded preparation, and if compounded, from which pharmacy. Verify the pharmacy through the state board of pharmacy, and check whether the company appears in the FDA warning letter database.
Bring a current medication and supplement list, personal and family history of thyroid cancer or endocrine tumors, and any history of pancreatitis, gallbladder disease or eating disorders to the first appointment.
Do not start, stop or adjust a prescribed medication based on an advertisement, a social media account or an endorsement. Severe abdominal pain radiating to the back, persistent vomiting, signs of dehydration or a neck lump warrant prompt medical evaluation rather than a message through an app.
Additional GLP-1 and combination agents are in late-stage trials, and coverage rules continue to shift. MedicalDaily will report approvals, label changes, and enforcement actions as they occur.
Key Questions Answered
What changed recently? Two oral GLP-1 medications are now approved for weight management, oral semaglutide in December 2025 and orforglipron on April 1 of this year, and the FDA has issued three major rounds of warning letters to telehealth companies over marketing of compounded versions.
Are compounded GLP-1 products the same as branded ones? No. Compounded preparations are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before sale.
Who should not take these medications? People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, among other contraindications a prescriber must assess.
What labs are typically ordered first? Hemoglobin A1c or fasting glucose, a comprehensive metabolic panel, a lipid panel, and, where relevant, thyroid function.
Why does resistance training come up? Weight loss on these medications includes lean mass, so protein intake and strength work are part of the treatment plan.
What happens if someone stops? Appetite regulation generally returns toward baseline and weight regain is expected, which is why a discontinuation plan should be discussed upfront.
Which symptoms need urgent evaluation? Severe abdominal pain radiating to the back, persistent vomiting, signs of dehydration, or a new neck lump.
